Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

ARTIS Ventures Closes $200M TechBio Fund to Support Next Era of Health & Medicine Innovation

What You Should Know: – ARTIS Ventures, a pioneer in this “TechBio” revolution, announces the closing of its second fund, TechBio II, with $200M focused

December 14, 2023

Discovery of TRPC5 gene’s role in obesity and postnatal depression offers hope for new treatments

Scientists have identified a gene which, when missing or impaired, can cause obesity, behavioral problems and, in mothers, postnatal depression. The discovery, reported today in Cell,

July 8, 2024

Opinion | Brain Health Risks: Digital Quality Measures and the Future of Neurological Care

Moura is a clinical neurologist and a health informatics expert. Ndemo is a clinical informatics manager. Weathers is a neurohospitalist and an associate chief medical

September 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.